Millipore "worth every Euro," says Merck CEO Kley

Merck KGaA CEO Karl-Ludwig Kley says following the late February announcement of the company's acquisition of biotech supplier Millipore, he was asked more than once if the $6 billion price was too high. "I have a clear answer: No, Millipore is worth every euro," he says, as quoted in BusinessWeek. He adds the takeover "will transform" Merck's life science chemicals division. Article

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.